Thursday, July 30, 2015 | 9 p.m.
The Cleveland Clinic Lou Ruvo Center for Brain Health is looking for people with mild to moderate forms of Alzheimer's disease to participate in a six-month study.
The participants would be part of a multicenter Alzheimer's disease treatment trial called Rasagiline Rescue (R2). Researchers hope to determine if treatment with rasagiline — an FDA-approved drug to treat Parkinson's disease — results in both improved brain glucose metabolism and memory.
Participants must be 50 to 90 years old and have a study partner willing and able to comply with required procedures and at least eight years of education.
The Alzheimer's Drug Discovery Foundation raised more than $1.2 million for the R2 study.
Contact Yolande Mucharbach at 702-685-7070 or [email protected] for more information about the R2 trial and how to enroll.